Ronan J. Kelly, MD

Articles by Ronan J. Kelly, MD

According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.

MATTERHORN Findings May Offer Additional Therapy Option in Gastric Cancers

June 16th 2025

According to Ronan J. Kelly, MD, MBA, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.

Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.

Nivolumab Exhibits Enhanced DFS Outcomes in Resected Gastric Cancers

ByRonan J. Kelly, MD

June 15th 2025

Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.

Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.

No Deaths Observed Related to Nivolumab in Resected Gastric Cancers

ByRonan J. Kelly, MD

June 14th 2025

Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.

Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma

ByDaniel V. T. Catenacci, MD,Yoon-Koo Kang, MD, PhD,Hope E. Uronis, MD, MHS,Keun-Wook Lee, MD, PhD,Matthew C. H. Ng, MD,Peter C. Enzinger, MD,Se Hoon Park, MD, PhD,Philip J. Gold, MD,Jill Lacy, MD,Howard S. Hochster, MD,Sang Cheul Oh, MD, PhD,Yeul Hong Kim, MD, PhD,Kristen A. Marrone, MD,Ronan J. Kelly, MD,Rosalyn A. Juergens, MD,Jong Gwang Kim, MD, PhD,Thierry Alcindor, MD, MSc,Sun Jin Sym, MD, PhD,Eun-Kee Song, MD, PhD,Cheng Ean Chee, MD,Yee Chao, MD, PhD,Sunnie Kim, MD,Do-Youn Oh, MD, PhD,Jennifer Yen, PhD,Justin I. Odegaard, MD, PhD,Errin Lagow, PhD,Daner Li, MS,Jichao Sun, PhD,Patrick Kaminker, PhD,Paul A. Moore, PhD,Minori Koshiji Rosales, MD, PhD,Haeseong Park, MD, MPH

April 27th 2023

Daniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.